Symposium

### TB in children

Drug-resistant TB care and treatment, including trials

This symposium aims to address practical and scientific aspects of the management of drug-resistant TB (DR-TB) in children, including novel approaches to prevention and treatment. Data will be presented from an evidence synthesis of current treatment modalities and outcomes, presenting cohorts from geographically diverse settings. Emerging data will be presented on the pharmacokinetics (PK) and safety of key second-line TB drugs in children. Early experiences with using novel drugs for MDR-TB in compassionate use programmes will be presented. An overview of planned and ongoing research will be given.

### Target audience

1. National TB programme personnel, clinicians
2. Paediatric care providers
3. Nongovernmental organisations, funders, pharma

### Objectives

1. Share planned and ongoing research strategies for paediatric MDR-TB
2. Disseminate best practices for the use of second-line drugs in children
3. Build on knowledge of existing cohorts to optimise treatment for paediatric MDR-TB
4. Share early experiences with the use of novel TB drugs for MDR-TB in children

### Keywords

MDR-TB; paediatric; treatment

### Coordinator(s)

Anneke Hesseling (South Africa), Hendrik Simon Schaaf (South Africa)

### Chair(s)

James Seddon (UK), Cherise Scott (USA)

### Presentations

**10:30 - 10:45** Update on planned and ongoing trials on MDR-TB prevention and treatment in children
Anneke Hesseling (South Africa)

**10:50 - 11:05** Global treatment outcomes in children with paediatric MDR-TB: systematic review and meta-analysis
Elizabeth Harausz (USA)

**11:10 - 11:25** Emerging data on PK and safety of levofloxacin and amikacin informs care and design of new regimens
Anthony Garcia-Prats (South Africa), Hendrik Simon Schaaf (South Africa)

**11:30 - 11:45** Compassionate use of bedaquiline and delamanid in children with MDR-and XDR-TB - early experiences and challenges
Marina Tadolini (Italy)

**11:50 - 12:00** Discussion